We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
Read MoreHide Full Article
Key Takeaways
Labcorp shares gained 14% in a month as earnings, revenues and operating margins improved.
Specialty testing posted double-digit growth in oncology, women's health, autoimmune disease and neurology.
Labcorp trades at 16.7X forward earnings, above its 14.4X five-year median but below its 17.8X high.
Labcorp Holdings Inc. (LH - Free Report) shares have gained 14% in the past month, sharpening the debate over how much upside remains after a rapid advance. The rally comes as the company is reporting better earnings, expanding margins and growth across both Diagnostics Laboratories and Biopharma Laboratory Services.
The operating picture has improved, but valuation has moved above Labcorp’s longer-term norm. That leaves investors weighing execution and business momentum against a higher bar for future results.
Labcorp’s One-Month Rally Sets a Higher Bar
Labcorp’s 14% four-week gain stands out against an already stronger operating backdrop. The company’s Diagnostics Laboratories business grew revenues 5.5% year over year in the second quarter, while Biopharma Laboratory Services, or BLS, advanced 6.5%.
The move does not establish that any single development drove the stock higher. It does, however, raise expectations as investors assess whether improving profitability, specialty testing demand and biopharma activity can sustain the recent momentum.
LH’s Q2 Results Add Fundamental Support
Second-quarter adjusted earnings were $4.99 per share, up 14.9% year over year and 4.2% above the Zacks Consensus Estimate. Revenues increased 5.8% to $3.73 billion and also topped the consensus mark.
Profitability improved with the top line. Adjusted operating income rose to $588.7 million from $531.6 million, while the enterprise adjusted operating margin expanded 70 basis points to 15.8%. The margin gain shows that revenue growth is translating into better operating leverage.
In the past 30 days, Labcorp’s 2026 earnings have moved north by 1.3% to $18.24.
Image Source: Zacks Investment Research
Labcorp’s Growth Drivers Still Have Room to Run
Specialty testing remains a central growth engine. Oncology, women’s health, autoimmune disease and neurology each delivered double-digit revenue growth during the first half of 2026, supporting new health-system and provider wins and a favorable test mix.
BLS adds another source of momentum. Second-quarter revenue rose 6.5% to $836.2 million, Central Laboratories revenue increased 9.8% and the segment’s adjusted operating margin reached 17%. Quest Diagnostics Incorporated (DGX - Free Report) , another large diagnostic testing provider, offers investors a direct industry comparison for laboratory demand and health-system relationships. Thermo Fisher Scientific Inc. (TMO - Free Report) also provides a relevant biopharma-services reference point through its broad pharmaceutical and clinical research capabilities.
LH’s Valuation Raises the Priced-In Question
Labcorp trades at 16.7X forward 12-month earnings, modestly above the Zacks sub-industry’s 16.2X multiple. It also sits well above its own five-year median of 14.4X, although the current multiple remains below the five-year high of 17.8X.
Image Source: Zacks Investment Research
That premium does not negate the company’s improving results, but it reduces the room for disappointment. Further upside will likely require continued earnings execution, sustained specialty and BLS growth and additional margin progress to justify a valuation already above Labcorp’s longer-term norm.
Labcorp’s Ratings Favor Momentum Over Growth
The near-term setup is balanced rather than one-sided. Labcorp currently carries a Zacks Rank #3 (Hold), which points to a neutral short-term earnings-revision backdrop rather than a clear buy or sell signal.
The Style Scores tilt more favorably toward momentum and value. Labcorp has a VGM Score of B, Momentum Score of A and Value Score of B, while its Growth Score is C. The mix fits the current tension: price momentum and valuation characteristics are favorable, but the pure-growth profile is less compelling. After the recent rally, execution remains important as investors weigh business progress against a richer valuation.
View the Zacks #1 Rank List
Image: Bigstock
Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation
Key Takeaways
Labcorp Holdings Inc. (LH - Free Report) shares have gained 14% in the past month, sharpening the debate over how much upside remains after a rapid advance. The rally comes as the company is reporting better earnings, expanding margins and growth across both Diagnostics Laboratories and Biopharma Laboratory Services.
The operating picture has improved, but valuation has moved above Labcorp’s longer-term norm. That leaves investors weighing execution and business momentum against a higher bar for future results.
Labcorp’s One-Month Rally Sets a Higher Bar
Labcorp’s 14% four-week gain stands out against an already stronger operating backdrop. The company’s Diagnostics Laboratories business grew revenues 5.5% year over year in the second quarter, while Biopharma Laboratory Services, or BLS, advanced 6.5%.
The move does not establish that any single development drove the stock higher. It does, however, raise expectations as investors assess whether improving profitability, specialty testing demand and biopharma activity can sustain the recent momentum.
LH’s Q2 Results Add Fundamental Support
Second-quarter adjusted earnings were $4.99 per share, up 14.9% year over year and 4.2% above the Zacks Consensus Estimate. Revenues increased 5.8% to $3.73 billion and also topped the consensus mark.
Profitability improved with the top line. Adjusted operating income rose to $588.7 million from $531.6 million, while the enterprise adjusted operating margin expanded 70 basis points to 15.8%. The margin gain shows that revenue growth is translating into better operating leverage.
In the past 30 days, Labcorp’s 2026 earnings have moved north by 1.3% to $18.24.
Image Source: Zacks Investment Research
Labcorp’s Growth Drivers Still Have Room to Run
Specialty testing remains a central growth engine. Oncology, women’s health, autoimmune disease and neurology each delivered double-digit revenue growth during the first half of 2026, supporting new health-system and provider wins and a favorable test mix.
BLS adds another source of momentum. Second-quarter revenue rose 6.5% to $836.2 million, Central Laboratories revenue increased 9.8% and the segment’s adjusted operating margin reached 17%. Quest Diagnostics Incorporated (DGX - Free Report) , another large diagnostic testing provider, offers investors a direct industry comparison for laboratory demand and health-system relationships. Thermo Fisher Scientific Inc. (TMO - Free Report) also provides a relevant biopharma-services reference point through its broad pharmaceutical and clinical research capabilities.
LH’s Valuation Raises the Priced-In Question
Labcorp trades at 16.7X forward 12-month earnings, modestly above the Zacks sub-industry’s 16.2X multiple. It also sits well above its own five-year median of 14.4X, although the current multiple remains below the five-year high of 17.8X.
Image Source: Zacks Investment Research
That premium does not negate the company’s improving results, but it reduces the room for disappointment. Further upside will likely require continued earnings execution, sustained specialty and BLS growth and additional margin progress to justify a valuation already above Labcorp’s longer-term norm.
Labcorp’s Ratings Favor Momentum Over Growth
The near-term setup is balanced rather than one-sided. Labcorp currently carries a Zacks Rank #3 (Hold), which points to a neutral short-term earnings-revision backdrop rather than a clear buy or sell signal.
The Style Scores tilt more favorably toward momentum and value. Labcorp has a VGM Score of B, Momentum Score of A and Value Score of B, while its Growth Score is C. The mix fits the current tension: price momentum and valuation characteristics are favorable, but the pure-growth profile is less compelling. After the recent rally, execution remains important as investors weigh business progress against a richer valuation.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.